Chugai Pharmaceutical (4519 JP): Actemra Loses Its Sheen on Arrival of Oral COVID-19 Pill
Chugai's COVID-19 drugs do not seem to be stack up well against the newly approved oral COVID-19 drugs in 2022 and beyond. The company has already...
634 Views
Liquid Universe of European Ordinary and Preferred Shares: December Report
Spreads have generally tightened across our liquid universe, with some notorious exceptions such as BMW, Sixt and Volkswagen. Roche seems the most...
513 Views
Nektar Therapeutics (NKTR US): A Good Buying Option in Immuno-Oncology Therapeutic Area
Nektar presented favorable clinical data for its lead candidate, bempeg at a global healthcare conference recently. Bempeg, a potential blockbuster...
375 Views
Novo Nordisk: Record Exposure, Moves to Largest Global Overweight
Exposure in Novo Nordisk A/S (NOVOB DC) hits all-time highs among active Global managers, overtakes Visa (V US) and Roche Holding Ag (ROG SE) as...
319 Views
BNC Korea (256840 KS): Oral COVID-19 Treatment No More Remains a Catalyst
In-licensed oral COVID-19 treatment no longer remains a catalyst after competitor's encouraging clinical trial results. Other oral treatments are...
206 Views